Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

byBenzinga Newsdesk

October 13, 2022

1 minute read

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

What’s Going On With Goldman Sachs and What’s The Sentiment for CEO David Solomon?

By Anusuya Lahiri

August 21, 9:37 AM

Goldman Sachs Inc (NYSE: GS) CEO David Solomon has recently

Analyst Ratings

Expert Ratings for RenaissanceRe Holdings

By Benzinga Insights

March 31, 3:01 PM

Analysts have provided the following ratings for RenaissanceRe Holdings (NYSE:RNR) within the last quarter: Bullish Somewhat Bullish Indifferent…

RNR

TransCode Therapeutics Announces Prolonged Survival In Murine Models With Glioblastoma Treated With Its Lead Candidate, TTX-MC138

By Benzinga Newsdesk

October 26, 8:20 AM

TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced significantly improved survival in murine models bearing human

RNAZ

Coca-Cola Gets Price Target Hikes By Analysts Following Better-Than-Expected Q1 Results

By Lisa Levin

April 25, 8:38 AM

The Coca-Cola Company (NYSE: KO) reported better-than-expected Q1 results.

Oppenheimer Downgrades Relmada Therapeutics to Perform

Related Posts

What’s Going On With Goldman Sachs and What’s The Sentiment for CEO David Solomon?

Expert Ratings for RenaissanceRe Holdings

TransCode Therapeutics Announces Prolonged Survival In Murine Models With Glioblastoma Treated With Its Lead Candidate, TTX-MC138

Coca-Cola Gets Price Target Hikes By Analysts Following Better-Than-Expected Q1 Results